PHARMARON BEIJING CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.16 CNY | +5.04% |
|
+1.54% | -33.89% |
| 10:54am | Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2% | MT |
| 10:42am | Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
19.16
CNY
Average target price
25.3
CNY
Spread / Average Target
+32.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.89% | 3.94B | |
| +1.51% | 42.59B | |
| +8.57% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +8.92% | 24.81B | |
| -25.13% | 18.17B | |
| +29.17% | 12.05B | |
| -3.12% | 11.7B | |
| +6.35% | 11.1B |
- Stock Market
- Equities
- 300759 Stock
- News Pharmaron Beijing Co., Ltd.
- Pharmaron Beijing : Raising $600 Million From Sale of Renminbi, US Dollar Convertible Bonds
